Hyperandrogenaemia and the ovary.
Hyperandrogenaemia in women presents in a variety of ways, including problems with the reproductive system. The commonest cause is polycystic ovary syndrome (PCOS), a condition found in 5-10% of all women. PCOS has origins that are genetic and environmental but the end organ, the ovary, exhibits excessive androgen production with enhanced sensitivity to luteinising hormone and insulin. Interventions include approaches that target both these hormones as well as the ovary itself.
Norman
Robert J
RJ
Reproductive Medicine Unit, Department of Obstetrics and Gynaecology, The University of Adelaide, The Queen Elizabeth Hospital, Woodville Road, Woodville, Australia. robert.norman@adelaide.edu.au
D000728:Androgens / Q000378:metabolism*; D002996:Clomiphene / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D007328:Insulin / Q000378:metabolism; D007986:Luteinizing Hormone / Q000494:pharmacology; D010053:Ovary / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000503:physiopathology / Q000628:therapy
D000728:Androgens; D004965:Estrogen Antagonists; D007328:Insulin; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone